SYRE – spyre therapeutics, inc. (US:NASDAQ)

News

Spyre Therapeutics (NASDAQ:SYRE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $70.00 price target on the stock.
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating [Yahoo! Finance]
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 [Yahoo! Finance]
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
Spyre Therapeutics' CEO Sells 15,000 Shares [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com